Glaucoma Therapeutics Market Scope And Analysis

Report Code : TIPRE00018828
Category : Life Sciences

Status : Published
No. of Pages : 150

Buy Now

Glaucoma Therapeutics Market Scope and Analysis by 2031

Buy Now

Glaucoma Therapeutics Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 6.24 Billion
Market Size by 2031	US$ 8.02 Billion
Global CAGR (2021 - 2031)	3.2%
Historical Data	2021-2022
Forecast period	2023-2031
Segments Covered	By Drug Class Beta Blockers Alpha Adrenergic Agonists Prostaglandins Analogues Carbonic Anhydrase Inhibitors Combination Drugs By Drug Class Beta Blockers Alpha Adrenergic Agonists Prostaglandins Analogues Carbonic Anhydrase Inhibitors Combination Drugs By Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Alcon AG AbbVie Inc Bausch Lomb Inc Fera Pharmaceuticals LLC Viatris Inc Novartis AG Sun Pharmaceutical Industries Ltd Teva Pharmaceutical Industries Ltd Thea Pharma Inc Santen Pharmaceutical Co Ltd

Glaucoma Therapeucs Market News and Recent Developments

The glaucoma therapeutics market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for glaucoma therapeutics:

The US Food and Drug Administration (FDA) approved Glaukos Corporation’s New Drug Application (NDA) for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG). (Source: Glaukos Corporation, Company News, 2023)
Alcon announced the acquisition of Aerie Pharmaceuticals, Inc. Through the transaction, the company acquired Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa (netarsudil ophthalmic solution) 0.02%, along with AR-15512, a Phase 3 product candidate for dry eye disease, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical product candidates. Rocklatan and Rhopressa are Rho-kinase inhibitors indicated for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. The acquisition is expected to broaden Alcon’s portfolio across glaucoma, retina, and ocular surface disease. (Source: Alcon, Press Release, 2022)

GLAUCOMA THERAPEUTICS Market Report Coverage and Deliverables

The “Glaucoma Therapeutics Market Size and Forecast (2022–2031)” report provides a detailed analysis of the market covering below areas:

Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
Market dynamics such as drivers, restraints, and key opportunities
Key future trends
Detailed PEST and SWOT analysis
Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
Detailed company profiles